COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

FDA Issues EUA for NGS Test to Identify T Cell Immunity for COVID-19

FDA maze of regulations
Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on whatsapp
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

New FDA authorization allows for T cell immunity testing for COVID-19

The US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for a new COVID-19-related test that is a first of its kind. This EUA was issued March 5, 2021, for Adaptive Biotechnologies’ T-Detect COVID Test.

The T-Detect COVID Test uses next-generation sequencing (NGS) to determine if an individual’s T cells have formed an immune response. Until now, many of the clinical tests used to assess immune response have focused on the presence of antibodies, not the T cells that produce them. This area of COVID-19 testing could potentially hold the key to long-term immunity.

Todays authorization further underscores the FDAs commitment to innovation in test development,” said Jeffrey Shuren, MD, JD, Director of FDAs Center for Devices and Radiological Health. The T-Detect COVID Test is a novel technology that assesses the T cell immune response to COVID-19. Information and scientific data that deepen our understanding of SARS-CoV-2 remain important keys to get ahead of this global pandemic.”

The ability to test for T-cell response can be used to indicate a recent or a prior SARS-CoV-2 infection while a negative test means this is unlikely. The FDA points out that this test should not be used for the diagnosis of an acute SARS-CoV-2 infection. The FDA also clearly states, “it is unknown how long the T cell immune response remains following infection and what level of protection may be provided by the presence of a T-cell immune response.”

While T-cell immunity is still a very active field of COVID-19 study, this new test now allows clinicians to offer T-cell COVID-19 testing for their patients.

Related Resources:


Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at


Robert L. Michel
President, Founder
The Dark Intelligence Group